Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nitroxoline

An orally bioavailable quinoline antibiotic, with potential antineoplastic activity. Upon oral administration, nitroxoline may induce apoptosis and inhibit tumor cell proliferation in NF1-null Schwann cells in neurofibromatosis type I through as of yet undisclosed mechanism of actions, other than inhibiting the RAS/mitogen-activated protein kinase (MAPK) pathway, and possibly through modulating mitochondrial function. NF1 encodes neurofibromin which inactivates Ras. Loss of neurofibromin in neurofibromatosis type I results in increased Ras activity, which promotes the transcription of genes that drives tumor cell growth and proliferation. As an antibiotic, nitroxoline inhibits bacterial RNA polymerase.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Nicene
Code name:HLX 1502
HLX-1502
HLX1502
Chemical structure:8-hydroxy-5-nitroquinoline
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search